MAPT and Alzheimer disease: Serum neurodegenerative biomarkers (total tau, phosphorylated tau-181, glial fibrillary acidic protein, neurofilament light chain) from hospitalized COVID-19 patients without dementia are elevated to levels observed in AD, and are associated with encephalopathy and worse outcomes [126].